 Antineoplastic Agents
"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 5 | 1 | 6 | | 1997 | 4 | 4 | 8 | | 1998 | 10 | 4 | 14 | | 1999 | 13 | 5 | 18 | | 2000 | 8 | 5 | 13 | | 2001 | 5 | 7 | 12 | | 2002 | 20 | 7 | 27 | | 2003 | 17 | 10 | 27 | | 2004 | 20 | 10 | 30 | | 2005 | 23 | 10 | 33 | | 2006 | 32 | 8 | 40 | | 2007 | 49 | 15 | 64 | | 2008 | 40 | 19 | 59 | | 2009 | 40 | 25 | 65 | | 2010 | 42 | 17 | 59 | | 2011 | 50 | 18 | 68 | | 2012 | 47 | 28 | 75 | | 2013 | 56 | 28 | 84 | | 2014 | 56 | 24 | 80 | | 2015 | 63 | 30 | 93 | | 2016 | 74 | 42 | 116 | | 2017 | 64 | 30 | 94 | | 2018 | 67 | 21 | 88 | | 2019 | 47 | 22 | 69 | | 2020 | 47 | 11 | 58 | | 2021 | 36 | 5 | 41 | | 2022 | 27 | 4 | 31 | | 2023 | 34 | 1 | 35 | | 2024 | 24 | 24 | 48 | | 2025 | 44 | 8 | 52 | | 2026 | 7 | 0 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Knudsen ES, Witkiewicz AK, Kabraji S. The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond. Nat Rev Drug Discov. 2026 Jul; 25(7):516-533.
-
Andrade-Bucknor S, Rodriguez BPR, Ma C, Lyubarova R, Kondapalli L. Imaging in Cardio-Oncology: Role of Novel Echo Parameters in Breast Cancer and Gynecologic Malignancies. Curr Cardiol Rep. 2026 Apr 23; 28(1).
-
Besse B, Subbiah V, Curigliano G, Bowles DW, Doebele RC, Mansfield AS, Baik CS, de Lima Lopes G, Paz-Ares L, Taylor MH, Tan DSW, Alonso G, Gadgeel SM, Kalemkerian GP, Ou SI, van der Wekken AJ, Becerra CR, Evangelist M, Griesinger F, Liu SV, Lou Y, Mazières J, Melear JM, Narang M, Saxena A, Thomas M, Wang S, Thomassen A, Lee DH, Kim DW, Gainor JF. Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer. J Clin Oncol. 2026 May; 44(13):1190-1197.
-
Kessler ER, Hoover K, Coats H, Fischer SM. Use of a Delphi process to formulate a pragmatic framework for care planning in older adults with advanced bladder cancer. Support Care Cancer. 2026 Mar 25; 34(4).
-
Morgenstern DA, Barone G, Corradini N, Federico SM, Flotho C, Gerber NU, Khaw SL, Macy ME, Place AE, Vo KT, Badawi M, Chen X, Luo A, Rocco MA, Ross JA, Scherer F, Sunkersett G, Onishi M, Goldsmith KC. Venetoclax in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results of a Phase 1 Study. Pediatr Blood Cancer. 2026 May; 73(5):e70178.
-
Schiavon A, Evaristo C, Saba L, Petiti J, Pignochino Y, Puglisi S, Perotti P, Messina E, Giachino C, Terzolo M, Lo Iacono M. Targeting ER stress in adrenocortical carcinoma: Celastrol as a novel therapeutic candidate. Biomed Pharmacother. 2026 Apr; 197:119156.
-
Jones MK, Sanchez J, Connor M, Julian K, Rezac R, Marciano K, Tobin J, Bosma G, Abbott D, Anttila K, Sohalski C, Belachew A, McMahon C, Kent A, Amaya M, Angelos MG, Schwartz M, Gutman JA, Pollyea DA. Tolerability and Outcomes With Serial Cycles of 28?Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia. Am J Hematol. 2026 Apr; 101(4):728-735.
-
Dimopoulos MA, Lonial S, Chng WJ, Iida S, Mateos MV, Morgan GJ, Li C, Byrne C, Suryanarayan K, Labotka R, Rajkumar SV. Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma. Blood Cancer J. 2025 Dec 04; 16(1):15.
-
Javle M, Fountzilas C, Liao CY, Pelster M, Li D, Deming D, Sahai V, Fonkoua LK, Cohn A, Mantry P, Richards D, Kingsley E, Wu F, Peng P, Hennessy K, Wang H, Sun C, Ni S, Fan J, Mahipal A. Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2026 Feb; 11(2):137-149.
-
Shulman DS, Vo KT, Balis FM, Lindsay H, Bagatell R, Place AE, Chi SN, Shusterman S, Ezrre S, Czaplinski J, Bhushan K, Kao PC, London WB, DuBois SG. A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors. Cancer Med. 2025 Dec; 14(23):e71417.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|